Practice

Breaking Down Biosimilar Barriers: Payer and PBM Policies

November 13th 2024

By Skylar Jeremias

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.

How Strategic IDNs Boost Biosimilar Adoption

November 10th 2024

By Skylar Jeremias

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption.

Making the Cost of IBD Care Sustainable

November 2nd 2024

By Deana Ferreri, PhD

Panelists Stress Stakeholder Education to Build Confidence in Biosimilars

October 31st 2024

By Skylar Jeremias

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.

Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry

October 29th 2024

By Skylar Jeremias

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.

Veterans’ Experience With Infliximab Biosimilars for IBD Treatment

October 26th 2024

By Deana Ferreri, PhD

A study of the Veterans Health Administration detailed their experience with infliximab biosimilars in a population of patients with inflammatory bowel disease (IBD) who were naive to infliximab.

Sandoz Report: A Unified Approach to Overcoming Drug Shortages

October 10th 2024

By Skylar Jeremias

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.

A Promise Unfulfilled: The State of Biosimilars

October 2nd 2024

By Mark Campbell, PharmD

For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.

AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2

September 24th 2024

By Skylar Jeremias

Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.

AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1

September 18th 2024

By Skylar Jeremias

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).